Literature DB >> 20952235

Geographical variation in human papillomavirus prevalence in Mexican women with normal cytology.

Asunción Orozco-Colín1, Adela Carrillo-García, Alfonso Méndez-Tenorio, Sergio Ponce-de-León, Alejandro Mohar, Rogelio Maldonado-Rodríguez, Rocío Guerra-Arias, Octavio Flores-Gil, Rita Sotelo-Regil, Marcela Lizano.   

Abstract

OBJECTIVE: To determine the prevalence of human papillomavirus (HPV) infection and genotype distribution in Mexican women with similar lifestyles from two geographical regions who receive medical care from the Mexican Navy Health System, and to identify the associated sociodemographic and reproductive characteristics.
METHODS: Cervical swabs from 671 women, beneficiaries of the Mexican Navy Health System, from two distinct southern coast regions of Mexico, were analyzed. Data were obtained regarding sociodemographic variables and sexual and reproductive history. For HPV detection and typing, PCR with general primers and direct sequencing were performed on extracted DNA. Association with clinical variables was evaluated.
RESULTS: Most patients had a normal cytology or low-grade intraepithelial neoplasia. A high prevalence of HPV was found (43.6%), with a significant difference between the two regions studied from the southwest Pacific coast of Mexico (37.6% in Acapulco, Guerrero vs. 49.7% in Lázaro Cárdenas, Michoacán). Some differences were also found associated to HPV type distribution, particularly related to genotypes 18, 58, and 53. Factors influencing these differences could not be identified with the analysis of typical risk factors linked to the acquisition of an HPV infection.
CONCLUSIONS: Regional differences in HPV prevalence and distribution show an apparent geographic boundary between the studied populations that deserves further analysis, taking into account other factors such as those related to the sexual partners.
Copyright © 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20952235     DOI: 10.1016/j.ijid.2010.07.007

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  19 in total

1.  Prevalence of human papillomavirus in women from Mexico City.

Authors:  María Guadalupe López Rivera; Maria Olivia Medel Flores; José D'Artagnan Villalba Magdaleno; Virginia Sánchez Monroy
Journal:  Infect Dis Obstet Gynecol       Date:  2012-07-02

2.  Prevalence of human papillomavirus types in North and Central regions of Mexico.

Authors:  C M Luna-Aguirre; L M Reyes-Cortés; A A Torres-Grimaldo; S F Karr-de-León; R M Cerda-Flores; B Melo-Nava; V E Aizpuru-Akel; H A Barrera-Saldaña
Journal:  Epidemiol Infect       Date:  2018-06-27       Impact factor: 4.434

3.  Epidemiological patterns of cervical human papillomavirus infection among women presenting for cervical cancer screening in North-Eastern Nigeria.

Authors:  Mohammed Mohammed Manga; Adeola Fowotade; Yusuf Mohammed Abdullahi; Aliyu Usman El-Nafaty; Danladi Bojude Adamu; Hamidu Umar Pindiga; Rasheed Ajani Bakare; Abimbola Olu Osoba
Journal:  Infect Agent Cancer       Date:  2015-10-02       Impact factor: 2.965

4.  Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico.

Authors:  Samantha E Rudolph; Attila Lorincz; Cosette M Wheeler; Patti Gravitt; Eduardo Lazcano-Ponce; Leticia Torres-Ibarra; Leith León-Maldonado; Paula Ramírez; Berenice Rivera; Rubí Hernández; Eduardo L Franco; Jack Cuzick; Pablo Méndez-Hernández; Jorge Salmerón
Journal:  BMC Infect Dis       Date:  2016-09-01       Impact factor: 3.090

5.  Human papillomavirus genotypes and HPV-16 variants distribution among Tunisian women with normal cytology and squamous intraepithelial lesions.

Authors:  R Ghedira; W Mahfoudh; S Hadhri; S Gabbouj; I Bouanene; H Khairi; A Chaieb; R Khelifa; N Bouaouina; S Remadi; A A Elmi; D Bansal; A A Sultan; R Faleh; A Zakhama; L Chouchane; E Hassen
Journal:  Infect Agent Cancer       Date:  2016-12-01       Impact factor: 2.965

6.  Relative frequency of human papillomavirus genotypes and related sociodemographic characteristics in women referred to a general hospital in Tehran, 2014-2015: A cross-sectional study.

Authors:  Mahin Jamshidi Makiani; Sara Minaeian; Soheila Amini Moghaddam; Seyed Akbar Moosavi; Zahra Moeini; Vajihe Zamani; Mahnaz Karbalaei Sabbagh; Hosein Forghani
Journal:  Int J Reprod Biomed       Date:  2017-05

7.  Prevalence and correlation of human papillomavirus genotypes with clinical factors in cervical samples from Mexican women.

Authors:  Fabiola Hernández-Rosas; Erika Orozco-Hernández; Liliana Maza-Sánchez; Pamela Citlalli Salgado-García; Enrique Navarro-Vidal; Mercedes Piedad de León-Bautista
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-22

8.  Prevalence of human papillomavirus in the cervical epithelium of Mexican women: meta-analysis.

Authors:  Raúl Peralta-Rodríguez; Pablo Romero-Morelos; Vanessa Villegas-Ruíz; Mónica Mendoza-Rodríguez; Keiko Taniguchi-Ponciano; Beatriz González-Yebra; Daniel Marrero-Rodríguez; Mauricio Salcedo
Journal:  Infect Agent Cancer       Date:  2012-12-03       Impact factor: 2.965

Review 9.  Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV.

Authors:  Simona Di Mario; Vittorio Basevi; Pier Luigi Lopalco; Sara Balduzzi; Roberto D'Amico; Nicola Magrini
Journal:  J Immunol Res       Date:  2015-08-25       Impact factor: 4.818

10.  The impact of glucocorticoids and anti-cd20 therapy on cervical human papillomavirus infection risk in women with systemic lupus erythematosus.

Authors:  Claudia Mendoza-Pinto; Mario Garcia-Carrasco; Veronica Vallejo-Ruiz; Alejandro Taboada-Cole; Margarita Muñoz-Guarneros; Juan Carlos Solis-Poblano; Elias Pezzat-Said; Adriana Aguilar-Lemarroy; Luis Felipe Jave-Suarez; Luis Vazquez de Lara; Gloria Ramos-Alvarez; Julio Reyes-Leyva; Aurelio Lopez-Colombo
Journal:  Clinics (Sao Paulo)       Date:  2013-12       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.